Osteopore signed an exclusive five-year contract sales and marketing agreement with DKSH (SIX:DKSH) to promote Osteopore’s off-the-shelf orthopedic products in Singapore. The agreement comes on the heels of Singapore market approvals for Osteopore’s orthopedic products in March 2024. . DKSH is a Switzerland-based holding company specializing in market expansion services, with a presence in 36 markets and 29,040 specialized staff.
Osteopore’s High Tibial Osteotomy (HTO) product is the centerpiece of the company’s orthopedic expansion into Singapore. Clinical performance data shows accelerated bone union with the Osteopore HTO product when compared to allogeneic fillers.
Commenting on Osteopore’s promising exclusive agreement with DKSH, Osteopore CEO, Dr. Lim Yujing, said, “Partnering with a company which boasts the channel access, resources and experience of DKSH, is a significant opportunity to commercialise our products in a meaningful and sustainable way. Early clinical results for HTO provide partners like DKSH with the confidence to launch a quality product, and we look forward to growing this market segment collaboratively with DKSH,” said Dr Lim.
Osteopore signed an exclusive five-year contract sales and marketing agreement with DKSH (SIX:DKSH) to promote Osteopore’s off-the-shelf orthopedic products in Singapore. The agreement comes on the heels of Singapore market approvals for Osteopore’s orthopedic products in March 2024. . DKSH is a Switzerland-based holding company specializing in...
Osteopore signed an exclusive five-year contract sales and marketing agreement with DKSH (SIX:DKSH) to promote Osteopore’s off-the-shelf orthopedic products in Singapore. The agreement comes on the heels of Singapore market approvals for Osteopore’s orthopedic products in March 2024. . DKSH is a Switzerland-based holding company specializing in market expansion services, with a presence in 36 markets and 29,040 specialized staff.
Osteopore’s High Tibial Osteotomy (HTO) product is the centerpiece of the company’s orthopedic expansion into Singapore. Clinical performance data shows accelerated bone union with the Osteopore HTO product when compared to allogeneic fillers.
Commenting on Osteopore’s promising exclusive agreement with DKSH, Osteopore CEO, Dr. Lim Yujing, said, “Partnering with a company which boasts the channel access, resources and experience of DKSH, is a significant opportunity to commercialise our products in a meaningful and sustainable way. Early clinical results for HTO provide partners like DKSH with the confidence to launch a quality product, and we look forward to growing this market segment collaboratively with DKSH,” said Dr Lim.
Copy to clipboard 
